Brilinta Tablets 60mg/90mg Clinical Experience Investigation
Phase of Trial: Phase IV
Latest Information Update: 05 Aug 2018
At a glance
- Drugs Ticagrelor (Primary)
- Indications Acute coronary syndromes; Myocardial infarction
- Focus Adverse reactions; Therapeutic Use
- Acronyms BRLCEIACS/OMI
- Sponsors AstraZeneca
- 27 Dec 2017 Planned End Date changed from 28 Aug 2024 to 21 Aug 2024.
- 27 Dec 2017 Planned primary completion date changed from 28 Aug 2024 to 21 Aug 2024.
- 27 Dec 2017 Status changed from not yet recruiting to recruiting.